APO Research
Talk to an analyst

APO RESEARCH · REPORT

Drugs for the Treatment of Refractory Gout

Compare research editions
View pricing & licenses

Selected research

Industry Research

Drugs for the Treatment of Refractory Gout Industry Research Report 2026

27 December 2025122 pages

Choose your research edition.

Industry ResearchDrugs for the Treatment of Refractory Gout Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Drugs for the Treatment of Refractory Gout Industry Growth and Trends Forecast to 2032105 pages · $3,450 USDMarket StructureGlobal Drugs for the Treatment of Refractory Gout Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Drugs for the Treatment of Refractory Gout Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Drugs for the Treatment of Refractory Gout Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Drugs for the Treatment of Refractory Gout market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Drugs for the Treatment of Refractory Gout is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Drugs for the Treatment of Refractory Gout is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Drugs for the Treatment of Refractory Gout is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Drugs for the Treatment of Refractory Gout include Zhuhai Livzon Biotechnology, Sobi, Qilu Pharmaceutical, Roche, Bio-Thera Solutions, Sandoz, Pfizer, Novartis and Kiniksa Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Drugs for the Treatment of Refractory Gout market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Drugs for the Treatment of Refractory Gout Market by Company

Zhuhai Livzon Biotechnology

Sobi

Qilu Pharmaceutical

Roche

Bio-Thera Solutions

Sandoz

Pfizer

Novartis

Kiniksa Pharmaceuticals

Horizo​​n Therapeutics

Hanwha Chemical

Fresenius Kabi

Biogen

Amgen

Drugs for the Treatment of Refractory Gout Segment by Type

Tumor Necrosis Factor Inhibitors

PEGylated Recombinant Uricase

Interleukin Inhibitors

Other

Drugs for the Treatment of Refractory Gout Segment by Application

Hospital and Clinic

Retail Pharmacies

Other

Drugs for the Treatment of Refractory Gout Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs for the Treatment of Refractory Gout market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Drugs for the Treatment of Refractory Gout and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs for the Treatment of Refractory Gout.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Drugs for the Treatment of Refractory Gout manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Drugs for the Treatment of Refractory Gout by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Drugs for the Treatment of Refractory Gout in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Drugs for the Treatment of Refractory Gout Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Drugs for the Treatment of Refractory Gout Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Drugs for the Treatment of Refractory Gout Sales Market Share by Manufacturers (2021-2026) Table 8. Global Drugs for the Treatment of Refractory Gout Revenue of Manufacturers (2021-2026) Table 9. Global Drugs for the Treatment of Refractory Gout Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Drugs for the Treatment of Refractory Gout Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Drugs for the Treatment of Refractory Gout Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Drugs for the Treatment of Refractory Gout, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Drugs for the Treatment of Refractory Gout, Product Type & Application Table 14. Global Drugs for the Treatment of Refractory Gout Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Drugs for the Treatment of Refractory Gout by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Zhuhai Livzon Biotechnology Company Information Table 19. Zhuhai Livzon Biotechnology Business Overview Table 20. Zhuhai Livzon Biotechnology Drugs for the Treatment of Refractory Gout Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Zhuhai Livzon Biotechnology Drugs for the Treatment of Refractory Gout Product Portfolio Table 22. Zhuhai Livzon Biotechnology Recent Developments Table 23. Sobi Company Information Table 24. Sobi Business Overview Table 25. Sobi Drugs for the Treatment of Refractory Gout Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Sobi Drugs for the Treatment of Refractory Gout Product Portfolio Table 27. Sobi Recent Developments Table 28. Qilu Pharmaceutical Company Information Table 29. Qilu Pharmaceutical Business Overview Table 30. Qilu Pharmaceutical Drugs for the Treatment of Refractory Gout Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Qilu Pharmaceutical Drugs for the Treatment of Refractory Gout Product Portfolio Table 32. Qilu Pharmaceutical Recent Developments Table 33. Roche Company Information Table 34. Roche Business Overview Table 35. Roche Drugs for the Treatment of Refractory Gout Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Roche Drugs for the Treatment of Refractory Gout Product Portfolio Table 37. Roche Recent Developments Table 38. Bio-Thera Solutions Company Information Table 39. Bio-Thera Solutions Business Overview Table 40. Bio-Thera Solutions Drugs for the Treatment of Refractory Gout Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Bio-Thera Solutions Drugs for the Treatment of Refractory Gout Product Portfolio Table 42. Bio-Thera Solutions Recent Developments Table 43. Sandoz Company Information Table 44. Sandoz Business Overview Table 45. Sandoz Drugs for the Treatment of Refractory Gout Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Sandoz Drugs for the Treatment of Refractory Gout Product Portfolio Table 47. Sandoz Recent Developments Table 48. Pfizer Company Information Table 49. Pfizer Business Overview Table 50. Pfizer Drugs for the Treatment of Refractory Gout Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Pfizer Drugs for the Treatment of Refractory Gout Product Portfolio Table 52. Pfizer Recent Developments Table 53. Novartis Company Information Table 54. Novartis Business Overview Table 55. Novartis Drugs for the Treatment of Refractory Gout Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Novartis Drugs for the Treatment of Refractory Gout Product Portfolio Table 57. Novartis Recent Developments Table 58. Kiniksa Pharmaceuticals Company Information Table 59. Kiniksa Pharmaceuticals Business Overview Table 60. Kiniksa Pharmaceuticals Drugs for the Treatment of Refractory Gout Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Kiniksa Pharmaceuticals Drugs for the Treatment of Refractory Gout Product Portfolio Table 62. Kiniksa Pharmaceuticals Recent Developments Table 63. Horizo​​n Therapeutics Company Information Table 64. Horizo​​n Therapeutics Business Overview Table 65. Horizo​​n Therapeutics Drugs for the Treatment of Refractory Gout Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Horizo​​n Therapeutics Drugs for the Treatment of Refractory Gout Product Portfolio Table 67. Horizo​​n Therapeutics Recent Developments Table 68. Hanwha Chemical Company Information Table 69. Hanwha Chemical Business Overview Table 70. Hanwha Chemical Drugs for the Treatment of Refractory Gout Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Hanwha Chemical Drugs for the Treatment of Refractory Gout Product Portfolio Table 72. Hanwha Chemical Recent Developments Table 73. Fresenius Kabi Company Information Table 74. Fresenius Kabi Business Overview Table 75. Fresenius Kabi Drugs for the Treatment of Refractory Gout Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Fresenius Kabi Drugs for the Treatment of Refractory Gout Product Portfolio Table 77. Fresenius Kabi Recent Developments Table 78. Biogen Company Information Table 79. Biogen Business Overview Table 80. Biogen Drugs for the Treatment of Refractory Gout Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Biogen Drugs for the Treatment of Refractory Gout Product Portfolio Table 82. Biogen Recent Developments Table 83. Amgen Company Information Table 84. Amgen Business Overview Table 85. Amgen Drugs for the Treatment of Refractory Gout Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Amgen Drugs for the Treatment of Refractory Gout Product Portfolio Table 87. Amgen Recent Developments Table 88. Global Drugs for the Treatment of Refractory Gout Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 89. Global Drugs for the Treatment of Refractory Gout Sales by Region (2021-2026) & (K Units) Table 90. Global Drugs for the Treatment of Refractory Gout Sales Market Share by Region (2021-2026) Table 91. Global Drugs for the Treatment of Refractory Gout Sales by Region (2027-2032) & (K Units) Table 92. Global Drugs for the Treatment of Refractory Gout Sales Market Share by Region (2027-2032) Table 93. Global Drugs for the Treatment of Refractory Gout Revenue by Region (2021-2026) & (US$ Million) Table 94. Global Drugs for the Treatment of Refractory Gout Revenue Market Share by Region (2021-2026) Table 95. Global Drugs for the Treatment of Refractory Gout Revenue by Region (2027-2032) & (US$ Million) Table 96. Global Drugs for the Treatment of Refractory Gout Revenue Market Share by Region (2027-2032) Table 97. North America Drugs for the Treatment of Refractory Gout Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 98. North America Drugs for the Treatment of Refractory Gout Sales by Country (2021-2026) & (K Units) Table 99. North America Drugs for the Treatment of Refractory Gout Sales by Country (2027-2032) & (K Units) Table 100. North America Drugs for the Treatment of Refractory Gout Revenue by Country (2021-2026) & (US$ Million) Table 101. North America Drugs for the Treatment of Refractory Gout Revenue by Country (2027-2032) & (US$ Million) Table 102. Europe Drugs for the Treatment of Refractory Gout Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 103. Europe Drugs for the Treatment of Refractory Gout Sales by Country (2021-2026) & (K Units) Table 104. Europe Drugs for the Treatment of Refractory Gout Sales by Country (2027-2032) & (K Units) Table 105. Europe Drugs for the Treatment of Refractory Gout Revenue by Country (2021-2026) & (US$ Million) Table 106. Europe Drugs for the Treatment of Refractory Gout Revenue by Country (2027-2032) & (US$ Million) Table 107. Asia Pacific Drugs for the Treatment of Refractory Gout Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 108. Asia Pacific Drugs for the Treatment of Refractory Gout Sales by Country (2021-2026) & (K Units) Table 109. Asia Pacific Drugs for the Treatment of Refractory Gout Sales by Country (2027-2032) & (K Units) Table 110. Asia Pacific Drugs for the Treatment of Refractory Gout Revenue by Country (2021-2026) & (US$ Million) Table 111. Asia Pacific Drugs for the Treatment of Refractory Gout Revenue by Country (2027-2032) & (US$ Million) Table 112. South America Drugs for the Treatment of Refractory Gout Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 113. South America Drugs for the Treatment of Refractory Gout Sales by Country (2021-2026) & (K Units) Table 114. South America Drugs for the Treatment of Refractory Gout Sales by Country (2027-2032) & (K Units) Table 115. South America Drugs for the Treatment of Refractory Gout Revenue by Country (2021-2026) & (US$ Million) Table 116. South America Drugs for the Treatment of Refractory Gout Revenue by Country (2027-2032) & (US$ Million) Table 117. Middle East and Africa Drugs for the Treatment of Refractory Gout Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 118. Middle East and Africa Drugs for the Treatment of Refractory Gout Sales by Country (2021-2026) & (K Units) Table 119. Middle East and Africa Drugs for the Treatment of Refractory Gout Sales by Country (2027-2032) & (K Units) Table 120. Middle East and Africa Drugs for the Treatment of Refractory Gout Revenue by Country (2021-2026) & (US$ Million) Table 121. Middle East and Africa Drugs for the Treatment of Refractory Gout Revenue by Country (2027-2032) & (US$ Million) Table 122. Global Drugs for the Treatment of Refractory Gout Sales by Type (2021-2026) & (K Units) Table 123. Global Drugs for the Treatment of Refractory Gout Sales by Type (2027-2032) & (K Units) Table 124. Global Drugs for the Treatment of Refractory Gout Sales Market Share by Type (2021-2026) Table 125. Global Drugs for the Treatment of Refractory Gout Sales Market Share by Type (2027-2032) Table 126. Global Drugs for the Treatment of Refractory Gout Revenue by Type (2021-2026) & (US$ Million) Table 127. Global Drugs for the Treatment of Refractory Gout Revenue by Type (2027-2032) & (US$ Million) Table 128. Global Drugs for the Treatment of Refractory Gout Revenue Market Share by Type (2021-2026) Table 129. Global Drugs for the Treatment of Refractory Gout Revenue Market Share by Type (2027-2032) Table 130. Global Drugs for the Treatment of Refractory Gout Price by Type (2021-2026) & (US$/Unit) Table 131. Global Drugs for the Treatment of Refractory Gout Price by Type (2027-2032) & (US$/Unit) Table 132. Global Drugs for the Treatment of Refractory Gout Sales by Application (2021-2026) & (K Units) Table 133. Global Drugs for the Treatment of Refractory Gout Sales by Application (2027-2032) & (K Units) Table 134. Global Drugs for the Treatment of Refractory Gout Sales Market Share by Application (2021-2026) Table 135. Global Drugs for the Treatment of Refractory Gout Sales Market Share by Application (2027-2032) Table 136. Global Drugs for the Treatment of Refractory Gout Revenue by Application (2021-2026) & (US$ Million) Table 137. Global Drugs for the Treatment of Refractory Gout Revenue by Application (2027-2032) & (US$ Million) Table 138. Global Drugs for the Treatment of Refractory Gout Revenue Market Share by Application (2021-2026) Table 139. Global Drugs for the Treatment of Refractory Gout Revenue Market Share by Application (2027-2032) Table 140. Global Drugs for the Treatment of Refractory Gout Price by Application (2021-2026) & (US$/Unit) Table 141. Global Drugs for the Treatment of Refractory Gout Price by Application (2027-2032) & (US$/Unit) Table 142. Key Raw Materials Table 143. Raw Materials Key Suppliers Table 144. Drugs for the Treatment of Refractory Gout Distributors List Table 145. Drugs for the Treatment of Refractory Gout Customers List Table 146. Drugs for the Treatment of Refractory Gout Industry Trends Table 147. Drugs for the Treatment of Refractory Gout Industry Drivers Table 148. Drugs for the Treatment of Refractory Gout Industry Restraints Table 149. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Drugs for the Treatment of Refractory Gout Product Image Figure 5. Global Drugs for the Treatment of Refractory Gout Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Drugs for the Treatment of Refractory Gout Market Size (2021-2032) & (US$ Million) Figure 7. Global Drugs for the Treatment of Refractory Gout Sales (2021-2032) & (K Units) Figure 8. Global Drugs for the Treatment of Refractory Gout Average Price (US$/Unit) & (2021-2032) Figure 9. Tumor Necrosis Factor Inhibitors Product Image Figure 10. PEGylated Recombinant Uricase Product Image Figure 11. Interleukin Inhibitors Product Image Figure 12. Other Product Image Figure 13. Hospital and Clinic Product Image Figure 14. Retail Pharmacies Product Image Figure 15. Other Product Image Figure 16. Global Drugs for the Treatment of Refractory Gout Revenue Share by Manufacturers in 2025 Figure 17. Global Manufacturers of Drugs for the Treatment of Refractory Gout, Manufacturing Sites & Headquarters Figure 18. Global Top 5 and 10 Drugs for the Treatment of Refractory Gout Players Market Share by Revenue in 2025 Figure 19. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. Global Drugs for the Treatment of Refractory Gout Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 21. Global Drugs for the Treatment of Refractory Gout Sales by Region in 2025 Figure 22. Global Drugs for the Treatment of Refractory Gout Revenue by Region in 2025 Figure 23. North America Drugs for the Treatment of Refractory Gout Market Size by Country in 2025 Figure 24. North America Drugs for the Treatment of Refractory Gout Sales Market Share by Country (2021-2032) Figure 25. North America Drugs for the Treatment of Refractory Gout Revenue Market Share by Country (2021-2032) Figure 26. United States Drugs for the Treatment of Refractory Gout Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Canada Drugs for the Treatment of Refractory Gout Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Mexico Drugs for the Treatment of Refractory Gout Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Europe Drugs for the Treatment of Refractory Gout Market Size by Country in 2025 Figure 30. Europe Drugs for the Treatment of Refractory Gout Sales Market Share by Country (2021-2032) Figure 31. Europe Drugs for the Treatment of Refractory Gout Revenue Market Share by Country (2021-2032) Figure 32. Germany Drugs for the Treatment of Refractory Gout Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. France Drugs for the Treatment of Refractory Gout Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. U.K. Drugs for the Treatment of Refractory Gout Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Italy Drugs for the Treatment of Refractory Gout Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Russia Drugs for the Treatment of Refractory Gout Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Spain Drugs for the Treatment of Refractory Gout Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Netherlands Drugs for the Treatment of Refractory Gout Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Switzerland Drugs for the Treatment of Refractory Gout Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Sweden Drugs for the Treatment of Refractory Gout Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Poland Drugs for the Treatment of Refractory Gout Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Asia Pacific Drugs for the Treatment of Refractory Gout Market Size by Country in 2025 Figure 43. Asia Pacific Drugs for the Treatment of Refractory Gout Sales Market Share by Country (2021-2032) Figure 44. Asia Pacific Drugs for the Treatment of Refractory Gout Revenue Market Share by Country (2021-2032) Figure 45. China Drugs for the Treatment of Refractory Gout Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. Japan Drugs for the Treatment of Refractory Gout Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. South Korea Drugs for the Treatment of Refractory Gout Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. India Drugs for the Treatment of Refractory Gout Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Australia Drugs for the Treatment of Refractory Gout Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Taiwan Drugs for the Treatment of Refractory Gout Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Southeast Asia Drugs for the Treatment of Refractory Gout Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Southeast Asia Drugs for the Treatment of Refractory Gout Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. South America Drugs for the Treatment of Refractory Gout Market Size by Country in 2025 Figure 54. South America Drugs for the Treatment of Refractory Gout Sales Market Share by Country (2021-2032) Figure 55. South America Drugs for the Treatment of Refractory Gout Revenue Market Share by Country (2021-2032) Figure 56. Brazil Drugs for the Treatment of Refractory Gout Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Argentina Drugs for the Treatment of Refractory Gout Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Chile Drugs for the Treatment of Refractory Gout Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Middle East and Africa Drugs for the Treatment of Refractory Gout Market Size by Country in 2025 Figure 60. Middle East and Africa Drugs for the Treatment of Refractory Gout Sales Market Share by Country (2021-2032) Figure 61. Middle East and Africa Drugs for the Treatment of Refractory Gout Revenue Market Share by Country (2021-2032) Figure 62. Egypt Drugs for the Treatment of Refractory Gout Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. South Africa Drugs for the Treatment of Refractory Gout Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. Israel Drugs for the Treatment of Refractory Gout Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Türkiye Drugs for the Treatment of Refractory Gout Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. GCC Countries Drugs for the Treatment of Refractory Gout Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. Global Drugs for the Treatment of Refractory Gout Sales Market Share by Type (2021-2032) Figure 68. Global Drugs for the Treatment of Refractory Gout Revenue Market Share by Type (2021-2032) Figure 69. Global Drugs for the Treatment of Refractory Gout Price (US$/Unit) by Type (2021-2032) Figure 70. Global Drugs for the Treatment of Refractory Gout Sales Market Share by Application (2021-2032) Figure 71. Global Drugs for the Treatment of Refractory Gout Revenue Market Share by Application (2021-2032) Figure 72. Global Drugs for the Treatment of Refractory Gout Price (US$/Unit) by Application (2021-2032) Figure 73. Drugs for the Treatment of Refractory Gout Value Chain Figure 74. Drugs for the Treatment of Refractory Gout Production Mode & Process Figure 75. Direct Comparison with Distribution Share Figure 76. Distributors Profiles Figure 77. Drugs for the Treatment of Refractory Gout Industry Opportunities and Challenges

Scope & coverage.

Types
  • Tumor Necrosis Factor Inhibitors
  • PEGylated Recombinant Uricase
  • Interleukin Inhibitors
  • Other
Applications
  • Hospital and Clinic
  • Retail Pharmacies
  • Other
Companies covered
  • Zhuhai Livzon Biotechnology
  • Sobi
  • Qilu Pharmaceutical
  • Roche
  • Bio-Thera Solutions
  • Sandoz
  • Pfizer
  • Novartis
  • Kiniksa Pharmaceuticals
  • Horizo​​n Therapeutics
  • Hanwha Chemical
  • Fresenius Kabi
  • Biogen
  • Amgen

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Drugs for the Treatment of Refractory Gout Market Size (2021-2032)
  4. 2.2.2 Global Drugs for the Treatment of Refractory Gout Sales (2021-2032)
  5. 2.2.3 Global Drugs for the Treatment of Refractory Gout Market Average Price (2021-2032)
  6. 2.3 Drugs for the Treatment of Refractory Gout by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Tumor Necrosis Factor Inhibitors
  9. 2.3.3 PEGylated Recombinant Uricase
  10. 2.3.4 Interleukin Inhibitors
  11. 2.3.5 Other
  12. 2.4 Drugs for the Treatment of Refractory Gout by Application
  13. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  14. 2.4.2 Hospital and Clinic
  15. 2.4.3 Retail Pharmacies
  16. 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Drugs for the Treatment of Refractory Gout Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Drugs for the Treatment of Refractory Gout Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Drugs for the Treatment of Refractory Gout Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Drugs for the Treatment of Refractory Gout Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Drugs for the Treatment of Refractory Gout Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Drugs for the Treatment of Refractory Gout, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Drugs for the Treatment of Refractory Gout, Product Type & Application
  8. 3.8 Global Manufacturers of Drugs for the Treatment of Refractory Gout, Established Date
  9. 3.9 Global Drugs for the Treatment of Refractory Gout Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Zhuhai Livzon Biotechnology
  2. 4.1.1 Zhuhai Livzon Biotechnology Company Information
  3. 4.1.2 Zhuhai Livzon Biotechnology Business Overview
  4. 4.1.3 Zhuhai Livzon Biotechnology Drugs for the Treatment of Refractory Gout Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Zhuhai Livzon Biotechnology Drugs for the Treatment of Refractory Gout Product Portfolio
  6. 4.1.5 Zhuhai Livzon Biotechnology Recent Developments
  7. 4.2 Sobi
  8. 4.2.1 Sobi Company Information
  9. 4.2.2 Sobi Business Overview
  10. 4.2.3 Sobi Drugs for the Treatment of Refractory Gout Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Sobi Drugs for the Treatment of Refractory Gout Product Portfolio
  12. 4.2.5 Sobi Recent Developments
  13. 4.3 Qilu Pharmaceutical
  14. 4.3.1 Qilu Pharmaceutical Company Information
  15. 4.3.2 Qilu Pharmaceutical Business Overview
  16. 4.3.3 Qilu Pharmaceutical Drugs for the Treatment of Refractory Gout Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Qilu Pharmaceutical Drugs for the Treatment of Refractory Gout Product Portfolio
  18. 4.3.5 Qilu Pharmaceutical Recent Developments
  19. 4.4 Roche
  20. 4.4.1 Roche Company Information
  21. 4.4.2 Roche Business Overview
  22. 4.4.3 Roche Drugs for the Treatment of Refractory Gout Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Roche Drugs for the Treatment of Refractory Gout Product Portfolio
  24. 4.4.5 Roche Recent Developments
  25. 4.5 Bio-Thera Solutions
  26. 4.5.1 Bio-Thera Solutions Company Information
  27. 4.5.2 Bio-Thera Solutions Business Overview
  28. 4.5.3 Bio-Thera Solutions Drugs for the Treatment of Refractory Gout Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Bio-Thera Solutions Drugs for the Treatment of Refractory Gout Product Portfolio
  30. 4.5.5 Bio-Thera Solutions Recent Developments
  31. 4.6 Sandoz
  32. 4.6.1 Sandoz Company Information
  33. 4.6.2 Sandoz Business Overview
  34. 4.6.3 Sandoz Drugs for the Treatment of Refractory Gout Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Sandoz Drugs for the Treatment of Refractory Gout Product Portfolio
  36. 4.6.5 Sandoz Recent Developments
  37. 4.7 Pfizer
  38. 4.7.1 Pfizer Company Information
  39. 4.7.2 Pfizer Business Overview
  40. 4.7.3 Pfizer Drugs for the Treatment of Refractory Gout Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Pfizer Drugs for the Treatment of Refractory Gout Product Portfolio
  42. 4.7.5 Pfizer Recent Developments
  43. 4.8 Novartis
  44. 4.8.1 Novartis Company Information
  45. 4.8.2 Novartis Business Overview
  46. 4.8.3 Novartis Drugs for the Treatment of Refractory Gout Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Novartis Drugs for the Treatment of Refractory Gout Product Portfolio
  48. 4.8.5 Novartis Recent Developments
  49. 4.9 Kiniksa Pharmaceuticals
  50. 4.9.1 Kiniksa Pharmaceuticals Company Information
  51. 4.9.2 Kiniksa Pharmaceuticals Business Overview
  52. 4.9.3 Kiniksa Pharmaceuticals Drugs for the Treatment of Refractory Gout Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Kiniksa Pharmaceuticals Drugs for the Treatment of Refractory Gout Product Portfolio
  54. 4.9.5 Kiniksa Pharmaceuticals Recent Developments
  55. 4.10 Horizo​​n Therapeutics
  56. 4.10.1 Horizo​​n Therapeutics Company Information
  57. 4.10.2 Horizo​​n Therapeutics Business Overview
  58. 4.10.3 Horizo​​n Therapeutics Drugs for the Treatment of Refractory Gout Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Horizo​​n Therapeutics Drugs for the Treatment of Refractory Gout Product Portfolio
  60. 4.10.5 Horizo​​n Therapeutics Recent Developments
  61. 4.11 Hanwha Chemical
  62. 4.11.1 Hanwha Chemical Company Information
  63. 4.11.2 Hanwha Chemical Business Overview
  64. 4.11.3 Hanwha Chemical Drugs for the Treatment of Refractory Gout Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Hanwha Chemical Drugs for the Treatment of Refractory Gout Product Portfolio
  66. 4.11.5 Hanwha Chemical Recent Developments
  67. 4.12 Fresenius Kabi
  68. 4.12.1 Fresenius Kabi Company Information
  69. 4.12.2 Fresenius Kabi Business Overview
  70. 4.12.3 Fresenius Kabi Drugs for the Treatment of Refractory Gout Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Fresenius Kabi Drugs for the Treatment of Refractory Gout Product Portfolio
  72. 4.12.5 Fresenius Kabi Recent Developments
  73. 4.13 Biogen
  74. 4.13.1 Biogen Company Information
  75. 4.13.2 Biogen Business Overview
  76. 4.13.3 Biogen Drugs for the Treatment of Refractory Gout Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Biogen Drugs for the Treatment of Refractory Gout Product Portfolio
  78. 4.13.5 Biogen Recent Developments
  79. 4.14 Amgen
  80. 4.14.1 Amgen Company Information
  81. 4.14.2 Amgen Business Overview
  82. 4.14.3 Amgen Drugs for the Treatment of Refractory Gout Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Amgen Drugs for the Treatment of Refractory Gout Product Portfolio
  84. 4.14.5 Amgen Recent Developments
5 Global Drugs for the Treatment of Refractory Gout Market Scenario by Region
  1. 5.1 Global Drugs for the Treatment of Refractory Gout Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Drugs for the Treatment of Refractory Gout Sales by Region: 2021-2032
  3. 5.2.1 Global Drugs for the Treatment of Refractory Gout Sales by Region: 2021-2026
  4. 5.2.2 Global Drugs for the Treatment of Refractory Gout Sales by Region: 2027-2032
  5. 5.3 Global Drugs for the Treatment of Refractory Gout Revenue by Region: 2021-2032
  6. 5.3.1 Global Drugs for the Treatment of Refractory Gout Revenue by Region: 2021-2026
  7. 5.3.2 Global Drugs for the Treatment of Refractory Gout Revenue by Region: 2027-2032
  8. 5.4 North America Drugs for the Treatment of Refractory Gout Market Facts & Figures by Country
  9. 5.4.1 North America Drugs for the Treatment of Refractory Gout Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Drugs for the Treatment of Refractory Gout Sales by Country (2021-2032)
  11. 5.4.3 North America Drugs for the Treatment of Refractory Gout Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Drugs for the Treatment of Refractory Gout Market Facts & Figures by Country
  16. 5.5.1 Europe Drugs for the Treatment of Refractory Gout Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Drugs for the Treatment of Refractory Gout Sales by Country (2021-2032)
  18. 5.5.3 Europe Drugs for the Treatment of Refractory Gout Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Drugs for the Treatment of Refractory Gout Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Drugs for the Treatment of Refractory Gout Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Drugs for the Treatment of Refractory Gout Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Drugs for the Treatment of Refractory Gout Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Drugs for the Treatment of Refractory Gout Market Facts & Figures by Country
  41. 5.7.1 South America Drugs for the Treatment of Refractory Gout Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Drugs for the Treatment of Refractory Gout Sales by Country (2021-2032)
  43. 5.7.3 South America Drugs for the Treatment of Refractory Gout Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Drugs for the Treatment of Refractory Gout Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Drugs for the Treatment of Refractory Gout Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Drugs for the Treatment of Refractory Gout Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Drugs for the Treatment of Refractory Gout Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Drugs for the Treatment of Refractory Gout Sales by Type (2021-2032)
  2. 6.1.1 Global Drugs for the Treatment of Refractory Gout Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Drugs for the Treatment of Refractory Gout Sales Market Share by Type (2021-2032)
  4. 6.2 Global Drugs for the Treatment of Refractory Gout Revenue by Type (2021-2032)
  5. 6.2.1 Global Drugs for the Treatment of Refractory Gout Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Drugs for the Treatment of Refractory Gout Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Drugs for the Treatment of Refractory Gout Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Drugs for the Treatment of Refractory Gout Sales by Application (2021-2032)
  2. 7.1.1 Global Drugs for the Treatment of Refractory Gout Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Drugs for the Treatment of Refractory Gout Sales Market Share by Application (2021-2032)
  4. 7.2 Global Drugs for the Treatment of Refractory Gout Revenue by Application (2021-2032)
  5. 7.2.1 Global Drugs for the Treatment of Refractory Gout Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Drugs for the Treatment of Refractory Gout Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Drugs for the Treatment of Refractory Gout Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Drugs for the Treatment of Refractory Gout Value Chain Analysis
  2. 8.1.1 Drugs for the Treatment of Refractory Gout Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Drugs for the Treatment of Refractory Gout Production Mode & Process
  5. 8.2 Drugs for the Treatment of Refractory Gout Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Drugs for the Treatment of Refractory Gout Distributors
  8. 8.2.3 Drugs for the Treatment of Refractory Gout Customers
9 Global Drugs for the Treatment of Refractory Gout Analyzing Market Dynamics
  1. 9.1 Drugs for the Treatment of Refractory Gout Industry Trends
  2. 9.2 Drugs for the Treatment of Refractory Gout Industry Drivers
  3. 9.3 Drugs for the Treatment of Refractory Gout Industry Opportunities and Challenges
  4. 9.4 Drugs for the Treatment of Refractory Gout Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst